Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in North America, Europe, and the Asia Pacific. It operates in two segments, Medical, and Nuclear & Safety. The Medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as product handling, medical imaging furniture, and rehabilitation products. This segment improves the quality and safety of cancer care delivery; and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools. The company's products and solutions also include radiation measurement and monitoring solutions, reactor instrumentation and control detectors, imaging systems and cameras, and waste management systems; laboratory and scientific analysis systems comprising gamma/alpha spectroscopy, alpha/beta counting, specialty detectors, and spectroscopy software; radiation measurement and health physics instrumentation; and contamination and clearance monitors. It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs. The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006. Mirion Technologies, Inc. was incorporated in 2005 and is headquartered in Atlanta, Georgia.

Mirion Technologies Inc. Class A

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zevra Therapeutics (ZVRA), Fate Therapeutics (FATE) ...

Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Fate Therapeutics (FATE) and Mirum Pharmaceuticals (MIRM)

Mirrabooka Investments Ltd ( ($AU:MIR) ) has issued an update. Mirrabooka Investments Limited has released an updated estimate of its pre-tax net t...

Mirrabooka reveals estimated NTA showing shares trade below asset backing

Mirum Pharmaceuticals received a Buy rating and an $115.00 price target from J.P. Morgan analyst today. The word on The Street in general, suggests...

Mirum Pharmaceuticals (MIRM) Gets a Buy from J.P. Morgan

Mirum Pharmaceuticals ( ($MIRM) ) just unveiled an announcement. On May 15, 2026, Mirum Pharmaceuticals issued $690 million of 0.00% Convertible Se...

Mirum Pharmaceuticals Issues $690 Million Convertible Senior Notes

In a report released today, Mani Foroohar from Leerink Partners maintained a Buy rating on Mirum Pharmaceuticals, with a price target of $154.00. A...

Leerink Partners Remains a Buy on Mirum Pharmaceuticals (MIRM)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright assigned a Buy rating to Mirum Pharmaceuticals, with a price target of $185...

Mirum Pharmaceuticals (MIRM) Gets a Buy from H.C. Wainwright

In a report released today, Lisa Walter from RBC Capital maintained a Buy rating on Mirum Pharmaceuticals, with a price target of $142.00. Accordin...

RBC Capital Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)

Mirrabooka Investments Ltd ( ($AU:MIR) ) has shared an announcement. Mirrabooka Investments reported an increase in its net tangible asset backing ...

Mirrabooka NTA Rises as Diversified Mid and Small-Cap Portfolio Grows

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on InflaRx (IFRX) and Mirum Pharmaceuticals (MIRM) with...

Analysts Are Bullish on These Healthcare Stocks: InflaRx (IFRX), Mirum Pharmaceuticals (MIRM)

The latest announcement is out from Mirum Pharmaceuticals ( ($MIRM) ). On May 4, 2026, Mirum Pharmaceuticals reported that its VISTAS Phase 2b tria...

Mirum’s Volixibat Succeeds in Phase 2b PSC Itch Trial

Mirion Technologies, Inc. (($MIR)) has held its Q1 earnings call. Read on for the main highlights of the call. Mirion Technologies’ latest earnings...

Mirion Technologies Earnings Call Shows Orders Surging

Mirriad Advertising ( ($GB:MIRI) ) has issued an announcement. Mirriad Advertising has placed its key U.K. operating subsidiary, Mirriad Limited, i...

Mirriad Becomes AIM Cash Shell After U.K. Unit Enters Administration

Analysts have been eager to weigh in on the Industrial Goods sector with new ratings on Mirion Technologies (MIR), Herc Holdings (HRI) and Lennox I...

Analysts’ Opinions Are Mixed on These Industrial Goods Stocks: Mirion Technologies (MIR), Herc Holdings (HRI) and Lennox International (LII)

Mirriad Advertising ( ($GB:MIRI) ) has issued an announcement. Mirriad Advertising has failed to secure the urgent funding needed to continue as a ...

Mirriad moves core subsidiaries into insolvency as funding bid fails

Mirrabooka Investments Ltd ( ($AU:MIR) ) just unveiled an update. Mirrabooka Investments Limited has reported an estimated pre-tax net tangible ass...

Current Quarter	$0.12	Next Quarter	$0.12
Current Year	$0.51	Next Year	$0.61
QoQ Growth	+0.0%	YoY Growth	+19.6%
3Y EPS CAGR	+27.8%	Target Price	$27.90
Consensus	Buy	Upside	+54.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MIR	$18.11	-1.34%	2.73M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MIR	$18.11	-1.3%	2.73M
3
4
5
6

MIR

MIR

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Mirion Technologies Inc. Class A Data in Excel

Get Mirion Technologies Inc. Class A Data in Excel